Racura Oncology Ltd (ASX:RAC)

Market Cap	432.37M +98.3%
Revenue (ttm)	6.04M +25.0%
Net Income	-4.79M
EPS	-0.03
Shares Out	181.67M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	87,805
Average Volume	156,948
Open	2.420
Previous Close	2.380
Day's Range	2.340 - 2.450
52-Week Range	0.920 - 4.900
Beta	0.91
RSI	49.63
Earnings Date	Feb 25, 2026

About Racura Oncology

Racura Oncology Ltd operates as a Phase 3 clinical biopharmaceutical company for cancer care. Its lead asset is RCDS1 (E,E-bisantrene), a small molecule anticancer agent that primarily functions through G4-DNA & RNA binding to potent inhibition of the cancer growth regulator MYC. The company is advancing a proprietary formulation of RCDS1 (RC220) to address the unmet needs of patients across various oncology indications with Phase 3 clinical programs in acute myeloid leukaemia, Phase 1a/b program in mutant epidermal growth factor receptor non-s...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: RAC

Financial Performance

In fiscal year 2025, Racura Oncology's revenue was 6.04 million, an increase of 24.96% compared to the previous year's 4.84 million. Losses were -4.79 million, -65.36% less than in 2024.